IMMUTEP LIMITED - AMERICAN DEPOSITARY SHARES
1.9200
21-February-25 16:45:00
15 minutes delayed
Stocks
-0.0500
-2.54%
Today's range
1.8800 - 1.9800
ISIN
N/A
Source
NASDAQ
-
Immutep’s Chinese Partner, Eoc Pharma, Expands Efti Trial Pipeline
31 Aug 2021 08:00:01 By Nasdaq GlobeNewswire
-
Immutep Announces Chinese Patent Grant for LAG-3 Antagonist Antibody LAG525
27 Aug 2021 08:00:00 By Nasdaq GlobeNewswire
-
05 Aug 2021 08:00:02 By Nasdaq GlobeNewswire
-
Immutep Quarterly Activities Report
13 Jul 2021 08:00:03 By Nasdaq GlobeNewswire
-
Immutep receives FDA and IRB approval in the US for Phase IIb TACTI-003 trial in HNSCC
06 Jul 2021 08:00:01 By Nasdaq GlobeNewswire
-
21 Jun 2021 08:00:00 By Nasdaq GlobeNewswire
-
21 Jun 2021 08:00:00 By Nasdaq GlobeNewswire
-
Immutep Reveals a New Anti-LAG-3 Research Program
08 Jun 2021 08:00:01 By Nasdaq GlobeNewswire
-
Immutep Reports Positive Data from its TACTI-002 Phase II Study of LAG-3 Therapy, Efti, at ASCO 2021
04 Jun 2021 08:00:01 By Nasdaq GlobeNewswire
-
04 Jun 2021 08:00:00 By Nasdaq GlobeNewswire